Reuters: http://ift.tt/2lFoUHQ
This comes after Bristol-Myers has added three directors to its board and bought back shares to appease JANA. That's all sounds great except that it seems Bristol-Meyers has a real competitive shortfalling right now and I'm not a huge fan of taking on debt to buy back shares. What are your thoughts? What does this mean for Bristol-Myers moving forward and are there any implications for their competition? Icahn thinks they are a potential take-over target. Are they priced right? Who would be making the move?
Submitted February 22, 2017 at 07:14AM by DogfaceDino http://ift.tt/2l7AWGF
